Cumberland Pharmaceuticals (CPIX)
Market Price (4/19/2026): $3.2 | Market Cap: $46.6 MilSector: Health Care | Industry: Pharmaceuticals
Cumberland Pharmaceuticals (CPIX)
Market Price (4/19/2026): $3.2Market Cap: $46.6 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% Attractive yieldFCF Yield is 7.7% Megatrend and thematic driversMegatrends include Specialty Pharmaceutical Development. Themes include Niche Drug Development & Commercialization, Acute Care & Hospital Therapeutics, and Gastroenterology & Autoimmune Specialty Drugs. | Weak multi-year price returns3Y Excs Rtn is -6.8% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.3% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% High stock price volatilityVol 12M is 101% Key risksCPIX key risks include [1] its reliance on the successful development and commercialization of its pipeline drug, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Attractive yieldFCF Yield is 7.7% |
| Megatrend and thematic driversMegatrends include Specialty Pharmaceutical Development. Themes include Niche Drug Development & Commercialization, Acute Care & Hospital Therapeutics, and Gastroenterology & Autoimmune Specialty Drugs. |
| Weak multi-year price returns3Y Excs Rtn is -6.8% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.3% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% |
| High stock price volatilityVol 12M is 101% |
| Key risksCPIX key risks include [1] its reliance on the successful development and commercialization of its pipeline drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant stock decline following the Q4 2025 earnings report and negative FY2026 EPS projection.
Cumberland Pharmaceuticals (CPIX) experienced a 19.9% stock decline the day after its Q4 2025 earnings announcement on March 3, 2026, despite reporting a 31% year-over-year revenue growth to $13.7 million for Q4 2025 and an 18% increase to $44.5 million for the full year 2025. This sharp drop was likely driven by the company's projection of a negative earnings per share (EPS) of $0.43 for fiscal year 2026, a significant downturn compared to the adjusted earnings of $0.11 per share for full-year 2025. This forward-looking guidance overshadowed the positive past performance and raised investor concerns about future profitability.
2. Increase in operating expenses impacting profitability.
Total operating expenses for Cumberland Pharmaceuticals increased to $47.3 million for the full year 2025, up from $44.3 million in the prior year. This rise in expenses, attributed to higher royalties, cost of goods, and other items associated with product sales growth, likely contributed to investor apprehension, especially in the context of the projected negative EPS for 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The -18.8% change in CPIX stock from 12/31/2025 to 4/18/2026 was primarily driven by a -26.8% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.98 | 3.23 | -18.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 41 | 45 | 7.9% |
| P/S Multiple | 1.4 | 1.1 | -26.8% |
| Shares Outstanding (Mil) | 15 | 15 | 2.8% |
| Cumulative Contribution | -18.8% |
Market Drivers
12/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| CPIX | -18.8% | |
| Market (SPY) | -5.4% | 15.2% |
| Sector (XLV) | -3.9% | 41.4% |
Fundamental Drivers
The 3.5% change in CPIX stock from 9/30/2025 to 4/18/2026 was primarily driven by a 5.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.12 | 3.23 | 3.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 42 | 45 | 5.8% |
| P/S Multiple | 1.1 | 1.1 | -4.8% |
| Shares Outstanding (Mil) | 15 | 15 | 2.8% |
| Cumulative Contribution | 3.5% |
Market Drivers
9/30/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| CPIX | 3.5% | |
| Market (SPY) | -2.9% | 11.0% |
| Sector (XLV) | 7.4% | 26.5% |
Fundamental Drivers
The -23.6% change in CPIX stock from 3/31/2025 to 4/18/2026 was primarily driven by a -32.3% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.23 | 3.23 | -23.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 38 | 45 | 17.6% |
| P/S Multiple | 1.6 | 1.1 | -32.3% |
| Shares Outstanding (Mil) | 14 | 15 | -4.0% |
| Cumulative Contribution | -23.6% |
Market Drivers
3/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| CPIX | -23.6% | |
| Market (SPY) | 16.3% | 14.7% |
| Sector (XLV) | 3.3% | 22.2% |
Fundamental Drivers
The 65.6% change in CPIX stock from 3/31/2023 to 4/18/2026 was primarily driven by a 58.0% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.95 | 3.23 | 65.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 42 | 45 | 6.0% |
| P/S Multiple | 0.7 | 1.1 | 58.0% |
| Shares Outstanding (Mil) | 14 | 15 | -1.1% |
| Cumulative Contribution | 65.6% |
Market Drivers
3/31/2023 to 4/18/2026| Return | Correlation | |
|---|---|---|
| CPIX | 65.6% | |
| Market (SPY) | 63.3% | 8.6% |
| Sector (XLV) | 20.3% | 8.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CPIX Return | 58% | -52% | -20% | 32% | 68% | -22% | 5% |
| Peers Return | -0% | -1% | -32% | -34% | -8% | 23% | -50% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 87% |
Monthly Win Rates [3] | |||||||
| CPIX Win Rate | 50% | 33% | 50% | 42% | 50% | 25% | |
| Peers Win Rate | 42% | 38% | 44% | 40% | 42% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CPIX Max Drawdown | -25% | -59% | -36% | -41% | -20% | -30% | |
| Peers Max Drawdown | -35% | -35% | -55% | -51% | -40% | -20% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HRTX, IRWD, PCRX, ASRT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)
How Low Can It Go
| Event | CPIX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -79.4% | -25.4% |
| % Gain to Breakeven | 385.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -45.6% | -33.9% |
| % Gain to Breakeven | 83.8% | 51.3% |
| Time to Breakeven | 385 days | 148 days |
| 2018 Correction | ||
| % Loss | -41.1% | -19.8% |
| % Gain to Breakeven | 69.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to HRTX, IRWD, PCRX, ASRT
In The Past
Cumberland Pharmaceuticals's stock fell -79.4% during the 2022 Inflation Shock from a high on 12/6/2021. A -79.4% loss requires a 385.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cumberland Pharmaceuticals (CPIX)
AI Analysis | Feedback
A specialty pharmaceutical company similar to **Jazz Pharmaceuticals**, but with a broader set of niche prescription drugs, particularly for hospital acute care.
Think of them as **Baxter International**, but specializing in developing and selling specific prescription drugs for hospitals, rather than a broad range of medical products.
AI Analysis | Feedback
- Acetadote: An injection used for the treatment of acetaminophen poisoning.
- Caldolor: An injection developed for the treatment of pain and fever.
- Kristalose: A prescription laxative oral solution for managing chronic and acute constipation.
- Omeclamox-Pak: Used for the treatment of Helicobacter pylori infection and duodenal ulcer disease.
- Vaprisol: An injection utilized for treating euvolemic and hypervolemic hyponatremia.
- Vibativ: An injection prescribed for the treatment of certain serious bacterial infections, including pneumonia and complicated skin infections.
- RediTrex: An injection under development for active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
AI Analysis | Feedback
Cumberland Pharmaceuticals (CPIX) sells prescription products primarily to other companies and healthcare institutions, rather than directly to individuals. Based on the provided background information, the company's major customers can be categorized as:
- Hospitals: Cumberland Pharmaceuticals focuses on "hospital acute care" and offers products such as Acetadote, Caldolor, Vaprisol, and Vibativ, which are typically administered in a hospital setting for acute conditions and serious infections.
- Gastroenterology Practices/Clinics: The company provides products for gastroenterology, including Kristalose (prescription laxative) and Omeclamox-Pak (for Helicobacter pylori infection), which would be prescribed and utilized in specialized gastroenterology clinics and physician offices.
- Rheumatology and Oncology Practices/Clinics: Cumberland Pharmaceuticals develops and offers products for rheumatology (e.g., RediTrex for various forms of arthritis and psoriasis) and oncology, indicating that specialized clinics and practices focusing on these therapeutic areas are key customers.
AI Analysis | Feedback
nullAI Analysis | Feedback
A.J. Kazimi, Chairman and Chief Executive Officer
A.J. Kazimi founded Cumberland Pharmaceuticals Inc. in 1999 and has served as its Chairman and Chief Executive Officer since the company's inception. Under his leadership, Cumberland oversaw the development and FDA approval of brands like Acetadote and Caldolor, and also led the acquisition of five other commercial products. He was responsible for the company's initial public offering and listing on the NASDAQ stock exchange. Before founding Cumberland, Mr. Kazimi spent eleven years as President and Chief Operating Officer of Therapeutic Antibodies Inc., an international biopharmaceutical company, contributing significantly to its growth from a start-up through its initial public offering on the London stock exchange. He began his career at Brown-Forman Corporation in various management roles. Mr. Kazimi also served on the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which was sold twice to large private equity investors. He also holds the position of Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee.
John M. Hamm, Vice President and Chief Financial Officer
John M. Hamm serves as the Vice President, Chief Financial Officer, and Principal Accounting Officer for Cumberland Pharmaceuticals.
James L. Herman, Vice President, Trade & Distribution and Chief Compliance Officer
James L. Herman holds the titles of Vice President, Trade & Distribution, and Chief Compliance Officer at Cumberland Pharmaceuticals.
Todd M. Anthony, Vice President, Organizational Development
Todd M. Anthony is the Vice President of Organizational Development for Cumberland Pharmaceuticals.
Chris T. Bitterman, Vice President, Sales and Marketing
Chris T. Bitterman serves as the Vice President of Sales and Marketing at Cumberland Pharmaceuticals.
AI Analysis | Feedback
The key risks to Cumberland Pharmaceuticals (CPIX) are primarily related to generic competition for its commercialized products, the inherent uncertainties of pharmaceutical product development, and significant customer concentration.
-
Generic Competition and Patent Expiration: Cumberland Pharmaceuticals faces a significant financial risk from generic products competing with its branded pharmaceutical products. Sales of established products can be adversely affected if generic alternatives are approved and marketed, potentially preventing the company from recovering the capital costs of bringing those products to market. For instance, increased generic competition has already impacted sales of Kristalose, with net revenue for this brand declining by 31% to $10.5 million, demonstrating the difficulty of maintaining market share against generics. While some products like Talicia have long patent protection through 2042, others like Acetadote had a key patent encompassing its EDTA-free formulation upheld until August 2025, suggesting a potential future impact from generic competition. Caldolor's patent is scheduled to expire in September 2029.
-
Clinical Trial Failure and Regulatory Hurdles for Pipeline Products: A substantial portion of Cumberland Pharmaceuticals' future growth relies on the successful development and regulatory approval of its pipeline products. The company has several product candidates in Phase II clinical trials, including ifetroban for various indications (e.g., Duchenne Muscular Dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis) and a cholesterol-reducing agent. Despite positive Phase II data for ifetroban in Duchenne Muscular Dystrophy cardiomyopathy, successful completion of later-stage clinical trials (Phase III) and subsequent regulatory approval by agencies like the FDA are not guaranteed. Failure to demonstrate efficacy or safety, or delays in the regulatory process, could result in significant investment losses and negatively impact the company's ability to introduce new revenue-generating products.
-
Customer Concentration Risk: Cumberland Pharmaceuticals faces a high risk due to extreme revenue concentration among a few key customers. Three wholesale customers generate 74% of the company's consolidated gross revenues. This exposes the business to significant counterparty risk, meaning that a loss of, or a material change in the purchasing strategies of, one or more of these major customers could have a severe adverse effect on Cumberland's revenue, cash flow, and overall financial stability.
AI Analysis | Feedback
nullAI Analysis | Feedback
Cumberland Pharmaceuticals Inc. (CPIX) markets a range of specialty pharmaceutical products, each targeting specific medical conditions with varying addressable market sizes.
Market Sizes for Cumberland Pharmaceuticals' Main Products:
- Acetadote (acetylcysteine injection): For the treatment of acetaminophen poisoning.
- The U.S. market for Acetadote® Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials, achieved annual sales of approximately $15.2 million for the 12-month period ending January 2025. The global acetylcysteine market was valued at USD 107 million in 2024 and is projected to reach USD 188 million by 2032. Other sources estimate the global acetylcysteine market at USD 2.1 billion in 2024, growing to USD 10.1 billion by 2033, or USD 1.6 billion in 2026, reaching USD 9.6 billion by 2035.
- Caldolor (ibuprofen injection): For the treatment of pain and fever.
- The global intravenous (IV) ibuprofen market size was valued at $5.34 million in 2020 and is projected to reach $15.48 million by 2030. Caldolor is noted as the sole injectable ibuprofen medication on the market in North America as of August 2025.
- Kristalose (lactulose oral solution): For the treatment of chronic and acute constipation.
- Kristalose generated $10.5 million in full-year product revenues for 2025 in the U.S.
- Omeclamox-Pak: For the treatment of Helicobacter pylori infection and duodenal ulcer disease.
- Null
- Vaprisol (conivaptan injection): For treating euvolemic and hypervolemic hyponatremia.
- Null
- Vibativ (telavancin injection): For the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- Vibativ generated $9.4 million in full-year product revenues for 2025. The product received marketing approval in China in February 2025, which is considered the world's second-largest market.
- RediTrex (methotrexate injection): For the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, and disabling psoriasis.
- The global methotrexate injection market size was valued at USD 555.30 million in 2024 and is expected to reach USD 681.88 million by 2032. The broader Global Disease-Modifying Antirheumatic Drug (DMARD) Market was estimated at US$ 20,671.1 million in 2022 and is expected to grow at a CAGR of 3.5% between 2022 and 2030. Cumberland launched RediTrex in the U.S. in November 2020.
- Ifetroban (product candidate in Phase II clinical trial):
- Systemic Sclerosis: The global systemic sclerosis market was valued at approximately USD 1,937 million in 2025 and is projected to grow to approximately USD 2,660 million by 2034. The United States accounted for nearly 75% of the total market size within the 7MM (seven major markets) in 2024.
- Duchenne Muscular Dystrophy (DMD): The global Duchenne muscular dystrophy treatment market size was valued at USD 4.63 billion in 2025 and is projected to reach USD 19.18 billion by 2034. The market size in the 7MM was around USD 2,150 million in 2023, with the United States accounting for the largest share at approximately USD 1,900 million.
- Hepatorenal Syndrome (HRS): The global hepatorenal syndrome treatment market size was approximately USD 14.62 billion in 2023 and is predicted to grow to around USD 25.07 billion by 2032. North America was the largest region in the hepatorenal syndrome treatment market in 2025.
- Portal Hypertension: The global portal hypertension management market is anticipated to reach US$ 4.97 billion by 2033, growing from US$ 3.05 billion in 2023. North America was the largest region in this market in 2025.
- Progressive Fibrosing Interstitial Lung Diseases (PF-ILD): The global PF-ILD treatment market is projected to be valued at USD 5,348.46 million in 2025 and is anticipated to reach USD 9,578.28 million by 2035. The therapeutic market size of PF-ILD in the 7MM was USD 4,205 million in 2021, with the U.S. accounting for approximately 73% of this total.
- Cholesterol Reducing Agent (hospital setting): The global cholesterol lowering drugs market was valued at USD 24,497.91 million in 2025 and is expected to increase to USD 35,854.74 million by 2032. Hospital pharmacies accounted for a major revenue share in the cholesterol lowering drugs market in 2021.
AI Analysis | Feedback
Cumberland Pharmaceuticals Inc. (CPIX) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and product advancements. Here are the key expected drivers of future revenue growth:- New Product Commercialization – Talicia: The recent launch and commercialization of Talicia, an FDA-approved treatment for Helicobacter pylori infection, is expected to be a significant revenue driver. Launched in the fourth quarter of 2025, Talicia generated initial revenues of $3.3 million for the full year. The collaboration with RedHill Biopharma Ltd. for joint commercialization, with Cumberland managing U.S. distribution, positions the company to capture market share in the gastroenterology sector, especially given the projected growth of the H. pylori infection market to $270 million by 2025, with the U.S. representing 85% of this market.
- International Market Expansion: Cumberland Pharmaceuticals is strategically expanding the global reach of its products. In 2025, Vibativ received regulatory approval in China and was launched in Saudi Arabia. The partnership with SciClone Pharmaceuticals for exclusive distribution rights in China, the world's second-largest pharmaceutical market, marks a substantial growth opportunity. Additionally, the company secured regulatory approval for its ibuprofen injection product in Mexico, facilitating expansion into the Latin American market.
- Continued Growth of Key Established Brands: Beyond new launches and international expansion, sustained demand and market acceptance of existing key products such as Vibativ and Sancuso are anticipated to drive revenue. Both products demonstrated significant growth in sales during 2025 and were highlighted as major contributors to the company's overall revenue increase.
- Advancement of Clinical Pipeline (Ifetroban): The progression of Cumberland's clinical pipeline, particularly with ifetroban, represents a future growth catalyst. Ifetroban is currently in Phase II clinical trials for various indications, including Duchenne muscular dystrophy (DMD) associated cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis. Positive top-line results from the FIGHT DMD clinical trial in early 2025, showing a 3.3% improvement in left ventricular ejection fraction, are promising, and the company plans to pursue ifetroban's registration for DMD-associated cardiomyopathy as its lead indication. While full commercialization may extend beyond the immediate 2-3 year horizon, continued positive clinical milestones and potential accelerated regulatory pathways could significantly impact future revenue expectations.
- Enhanced Market Access for Caldolor: Improved market access for Caldolor, an injection for pain and fever, is expected to contribute to revenue growth. The company successfully secured a J-code for Caldolor, which is designed to enhance hospital access and streamline the billing process. This improved accessibility is projected to drive increased sales of the product.
AI Analysis | Feedback
Outbound Investments
- Cumberland Pharmaceuticals expanded its presence in gastrointestinal care by adding Talicia, an FDA-approved treatment for Helicobacter pylori infections, to its commercial portfolio in 2025.
- The company acquired the assets and rights to Vaprisol, a prescription brand indicated for treating euvolemic and hypervolemic hyponatremia.
- Cumberland completed the transition of the Sancuso product, including the New Drug Application (NDA) transfer, from Kyowa Kirin, and subsequently expanded its oncology sales division to support the brand.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CPIX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.43 |
| Mkt Cap | 0.2 |
| Rev LTM | 155 |
| Op Inc LTM | -3 |
| FCF LTM | 4 |
| FCF 3Y Avg | 16 |
| CFO LTM | 5 |
| CFO 3Y Avg | 16 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.6% |
| Rev Chg 3Y Avg | 2.5% |
| Rev Chg Q | -0.5% |
| QoQ Delta Rev Chg LTM | -0.1% |
| Op Inc Chg LTM | 24.1% |
| Op Inc Chg 3Y Avg | -10.2% |
| Op Mgn LTM | -1.6% |
| Op Mgn 3Y Avg | -6.3% |
| QoQ Delta Op Mgn LTM | -2.3% |
| CFO/Rev LTM | 11.1% |
| CFO/Rev 3Y Avg | 10.0% |
| FCF/Rev LTM | 8.1% |
| FCF/Rev 3Y Avg | 10.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.2 |
| P/S | 1.2 |
| P/Op Inc | -6.7 |
| P/EBIT | -4.2 |
| P/E | -3.8 |
| P/CFO | 5.7 |
| Total Yield | -6.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 10.7% |
| D/E | 0.4 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 22.4% |
| 3M Rtn | -1.6% |
| 6M Rtn | 8.1% |
| 12M Rtn | 0.3% |
| 3Y Rtn | -59.2% |
| 1M Excs Rtn | 11.5% |
| 3M Excs Rtn | -4.6% |
| 6M Excs Rtn | -1.4% |
| 12M Excs Rtn | -32.7% |
| 3Y Excs Rtn | -132.6% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA050824 | OMECLAMOX-PAK | amoxicillin | capsule, tablet, capsule, delayed release | 2082011 | -17.6% | -6.1% | 8.2% | -29.5% | -48.2% |
| NDA022110 | VIBATIV | telavancin hydrochloride | powder | 9112009 | -13.5% | -27.7% | -68.8% | -63.7% | -79.7% |
| NDA022348 | CALDOLOR | ibuprofen | solution | 6112009 | |||||
| NDA022198 | SANCUSO | granisetron | film, extended release | 9122008 | |||||
| NDA022016 | VAPRISOL | conivaptan hydrochloride | injectable | 2282007 | |||||
Price Behavior
| Market Price | $3.23 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 08/11/2009 | |
| Distance from 52W High | -45.2% | |
| 50 Days | 200 Days | |
| DMA Price | $3.48 | $3.36 |
| DMA Trend | down | down |
| Distance from DMA | -7.1% | -3.8% |
| 3M | 1YR | |
| Volatility | 76.2% | 101.5% |
| Downside Capture | 0.48 | 0.76 |
| Upside Capture | -128.41 | 62.52 |
| Correlation (SPY) | 14.4% | 16.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.78 | 1.74 | 1.03 | 0.78 | 0.79 | 0.64 |
| Up Beta | 3.00 | 4.25 | 3.57 | 1.30 | 0.86 | 0.63 |
| Down Beta | 0.51 | 2.69 | 1.32 | 1.95 | 0.29 | 0.53 |
| Up Capture | -266% | 61% | -27% | 15% | 68% | 49% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 20 | 28 | 58 | 123 | 332 |
| Down Capture | 247% | 110% | 85% | 12% | 118% | 87% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 14 | 22 | 34 | 66 | 124 | 363 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CPIX | |
|---|---|---|---|---|
| CPIX | -11.7% | 101.3% | 0.34 | - |
| Sector ETF (XLV) | 9.6% | 16.0% | 0.39 | 21.5% |
| Equity (SPY) | 21.1% | 12.9% | 1.32 | 13.8% |
| Gold (GLD) | 50.9% | 27.5% | 1.49 | 6.2% |
| Commodities (DBC) | 25.2% | 16.2% | 1.40 | 2.2% |
| Real Estate (VNQ) | 17.5% | 13.7% | 0.93 | 16.2% |
| Bitcoin (BTCUSD) | -7.8% | 42.6% | -0.08 | 8.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CPIX | |
|---|---|---|---|---|
| CPIX | 3.3% | 113.5% | 0.44 | - |
| Sector ETF (XLV) | 6.4% | 14.6% | 0.25 | 5.1% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 5.7% |
| Gold (GLD) | 22.6% | 17.8% | 1.04 | 2.9% |
| Commodities (DBC) | 11.6% | 18.8% | 0.51 | 0.1% |
| Real Estate (VNQ) | 4.4% | 18.8% | 0.14 | 4.2% |
| Bitcoin (BTCUSD) | 5.2% | 56.5% | 0.31 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CPIX | |
|---|---|---|---|---|
| CPIX | -2.2% | 85.6% | 0.29 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 5.6% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 6.1% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 1.4% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 0.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 3.3% |
| Bitcoin (BTCUSD) | 68.4% | 66.9% | 1.07 | 1.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/3/2026 | -19.9% | -31.0% | -32.3% |
| 11/4/2025 | -12.4% | -24.8% | -10.2% |
| 8/5/2025 | -15.3% | -23.2% | -3.4% |
| 3/4/2025 | 11.9% | -14.5% | -29.3% |
| 11/7/2024 | -0.8% | 0.0% | 3.3% |
| 8/6/2024 | -1.3% | -8.0% | -12.7% |
| 3/5/2024 | -3.0% | -9.0% | -11.0% |
| 11/7/2023 | -11.7% | -18.0% | -19.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 3 | 5 |
| # Negative | 13 | 14 | 12 |
| Median Positive | 7.4% | 0.6% | 3.3% |
| Median Negative | -3.6% | -10.8% | -10.6% |
| Max Positive | 15.4% | 11.2% | 50.6% |
| Max Negative | -19.9% | -31.0% | -32.3% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Young, Caroline | Direct | Buy | 9122025 | 3.44 | 6 | 21 | 112,925 | Form | |
| 2 | Young, Caroline | Direct | Buy | 9122025 | 4.01 | 6 | 24 | 131,660 | Form | |
| 3 | Young, Caroline | Direct | Buy | 9122025 | 3.92 | 6 | 24 | 128,729 | Form | |
| 4 | Young, Caroline | Direct | Buy | 9122025 | 3.34 | 6 | 20 | 109,702 | Form | |
| 5 | Young, Caroline | Direct | Buy | 9122025 | 3.14 | 6 | 19 | 103,152 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.